Chiesi   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Parma Italy (1935)

Organization Overview

First Clinical Trial
2002
NCT00382889
First Marketed Drug
1988
nicardipine (cardene)
First NDA Approval
1996
zileuton (zyflo)
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

CHIESI | Chiesi España | Chiesi Farmaceutici | Chiesi Farmaceutici S.p.A. | Chiesi GmbH | Chiesi Pharmaceuticals | Chiesi Slovenija, d.o.o. | Chiesi UK | Chiesi USA | CHIESI USA INC | Innovair | Medical Department; Chiesi Farmaceutici S.p.A (Italy)

Active Ingredients

Marketed Drugs (8)

Key: Chiesi (6) Acquired (2)

cangrelor (kengreal) (2015)

clevidipine (cleviprex) (2008)

deferiprone (ferriprox) (2011)

mannitol (2020)

nicardipine (cardene) (1988)

poractant alfa (curosurf) (1999)

tobramycin (nebcin) (2012)

zileuton (zyflo) (1996 NDA)

Drugs in Phase 4 Trials (22)

Key: Chiesi (15) Acquired (7)

beclomethasone (vanceril) (62 trials)

cangrelor (kengreal) (3 trials)

chf1535 (18 trials)

chf 5993 (7 trials)

clevidipine (cleviprex) (1 trial)

dapsone (aczone) (4 trials)

fluticasone (cutivate) (11 trials)

formocortal (1 trial)

formoterol (foradil) (62 trials)

glycopyrronium (robinul) (25 trials)

labetalol (trandate) (1 trial)

metreleptin (myalept) (3 trials)

morphine (5 trials)

nicardipine (cardene) (1 trial)

poractant alfa (curosurf) (6 trials)

salmeterol (serevent) (8 trials)

tacrolimus (prograf) (6 trials)

tiotropium (spiriva) (6 trials)

tobramycin (nebcin) (5 trials)

verteporfin (visudyne) (10 trials)

vilanterol (Anoro Elipta) (2 trials)

zileuton (zyflo) (5 trials)

Drugs in Phase 3 Trials (33)

Key: Chiesi (17) Acquired (16)

adapalene (differin) (1 trial)

albuterol (proventil) (4 trials)

alteplase (Activase) (1 trial)

amlodipine (norvasc) (1 trial)

benzoyl peroxide (clearasil) (1 trial)

budesonide (rhinocort) (7 trials)

cabergoline (dostinex) (1 trial)

carboplatin (paraplatin) (1 trial)

cefotaxime (claforan) (1 trial)

chf6001 (13 trials)

clodronate disodium (1 trial)

crizotinib (xalkori) (2 trials)

cusa-081 (2 trials)

gentamicin (garamycin) (1 trial)

indalapril (1 trial)

lanreotide (somatuline depot) (1 trial)

lidocaine (xylocaine) (1 trial)

lixivaptan (6 trials)

lomitapide (juxtapid) (18 trials)

manidipine hydrochloride (1 trial)

meropenem (merrem) (2 trials)

octenidine (1 trial)

octreotide (sandostatin) (3 trials)

oleogel-s10 (6 trials)

paclitaxel (taxol) (1 trial)

pegaptanib (macugen) (1 trial)

procaine benzylpenicillin (novocaine) (1 trial)

roflumilast (daliresp) (3 trials)

symbicort (1 trial)

tariquidar (2 trials)

triamcinolone (kenalog) (4 trials)

velmanase alfa (10 trials)

vinorelbine (navelbine) (1 trial)

Drugs in Phase 2 Trials (44)

Key: Chiesi (19) Acquired (25)

aav5-hfix (1 trial)

arylsulfatase a (1 trial)

atorvastatin (lipitor) (5 trials)

bevacizumab (avastin) (2 trials)

buprenorphine (1 trial)

cenegermin-bkbj (oxervate) (1 trial)

chf 1531 (1 trial)

chf5074 (2 trials)

chf5259 (5 trials)

chf5633 (1 trial)

chf5992 (1 trial)

chf6297 (1 trial)

chf6366 (1 trial)

chf6563 (1 trial)

cyclosporine (sandimmune) (1 trial)

detox-b (1 trial)

dextromethorphan (delsym) (1 trial)

everolimus (zortress) (1 trial)

ezetimibe (zetia) (3 trials)

fenofibrate (fenoglide) (2 trials)

ghrp-1/ag (1 trial)

glybera (1 trial)

latanoprost (xalatan) (8 trials)

lemuteporfin (1 trial)

methylene blue (proveblue) (1 trial)

metronidazole (flagyl) (1 trial)

mycophenolate (myfortic) (1 trial)

niacin (1 trial)

oc000459 (1 trial)

oc-000459 (3 trials)

olopatadine (patanol) (1 trial)

omeprazole (prilosec) (1 trial)

porphozym (1 trial)

prednisone (meticorten) (1 trial)

pyruvic acid, ethyl ester (1 trial)

qlt0074 (1 trial)

ranibizumab (lucentis) (4 trials)

rhinovirus (strain 16) (1 trial)

simvastatin (zocor) (1 trial)

ta-2005 (5 trials)

timolol (blocadren) (4 trials)

umeclidinium (incruse ellipta) (1 trial)

urea (3 trials)

vitamin a (5 trials)

Drugs in Phase 1 Trials (9)

Key: Chiesi (5) Acquired (4)

atx2417 (1 trial)

chf6333 (2 trials)

chf6523 (1 trial)

cimetidine (tagamet) (1 trial)

ethinyl estradiol (Estinyl) (1 trial)

itraconazole (sporanox) (1 trial)

moxifloxacin (avelox) (2 trials)

norgestimate (1 trial)

surfactant (1 trial)

Drugs in Other Trials (2)

pegunigalsidase alfa (1 trial)

sodium chloride (1 trial)

Indications

Approved Indications


 

Asthma

Hypersensitivity

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Coronary Syndrome (Phase 4)

Acute Lung Injury (Phase 2)

alpha-Mannosidosis (Phase 3)

Alzheimer Disease (Phase 2)

Asthma (Phase 4)

Bronchiectasis (Phase 3)

Bronchopulmonary Dysplasia (Phase 4)

Cognitive Dysfunction (Phase 2)

Croup (Phase 3)

Cystic Fibrosis (Phase 4)

Emphysema (Phase 4)

Exocrine Pancreatic Insufficiency (Phase 2)

Fibrosis (Phase 4)

Foot Ulcer (Phase 2)

Heart Arrest (Phase 4)

Heart Diseases (Phase 1)

Hemophilia A (Phase 2)

Hemophilia B (Phase 2)

Hyperlipoproteinemia Type I (Phase 2)

Hyperplasia (Phase 4)

Hypertension (Phase 3)

Hypoplastic Left Heart Syndrome (Phase 1)

Idiopathic Pulmonary Fibrosis (Phase 2)

Infant, Premature, Diseases (Phase 4)

Infarction (Phase 4)

Kidney Failure, Chronic (Phase 4)

Lung Diseases (Phase 4)

Lung Diseases, Obstructive (Phase 4)

Mannosidase Deficiency Diseases (Phase 3)

Meningitis (Phase 2)

Metabolic Syndrome (Phase 2)

Myocardial Infarction (Phase 4)

Neonatal Abstinence Syndrome (Phase 2)

Obesity (Phase 2)

Osteoporosis (Phase 3)

Osteoporosis, Postmenopausal (Phase 3)

Out-of-Hospital Cardiac Arrest (Phase 4)

Pneumonia (Phase 4)

Pneumonia, Ventilator-Associated (Phase 4)

Pulmonary Disease, Chronic Obstructive (Phase 4)

Pulmonary Eosinophilia (Phase 3)

Pulmonary Fibrosis (Phase 2)

Respiratory Distress Syndrome (Phase 4)

Respiratory Distress Syndrome, Newborn (Phase 4)

Sepsis (Phase 3)

Sinusitis (Phase 3)

ST Elevation Myocardial Infarction (Phase 4)

Substance Withdrawal Syndrome (Phase 2)

Syndrome (Phase 4)

Thrombosis (Phase 3)

Tissue Adhesions (Phase 2)

Toxemia (Phase 3)

Ulcer (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 255
  • # of Trial APIs: 110